<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978519</url>
  </required_header>
  <id_info>
    <org_study_id>CRE 2020.018</org_study_id>
    <nct_id>NCT04978519</nct_id>
  </id_info>
  <brief_title>Effectiveness of Cryotherapy Study for Prostate Cancer</brief_title>
  <official_title>Evaluation of the Effectiveness of Cryotherapy for the Treatment of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre prospective, non-randomized trial to investigate the efficacy of&#xD;
      cryotherapy in patients with localized prostate cancer.The aim of study is to investigate the&#xD;
      safety profile of cryotherapy in the treatment of prostate cancer and to evaluate the&#xD;
      oncological control of prostate cancer by means of cryotherapy focal treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conventional treatment options for localized prostate cancer include prostatectomy,&#xD;
      radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain&#xD;
      degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and&#xD;
      injury to the structures in the proximity. Active surveillance carries the risk of disease&#xD;
      progression and psychological distress to the patients. Focal therapy employs the concept of&#xD;
      only destroying the significant lesion, resulting in disease cure and improved functional&#xD;
      outcome. Among the different options of focal therapy, cryotherapy is one of the most&#xD;
      commonly employed energy sources. It exerts its effect through freezing of tissue and&#xD;
      vascular injury, leading to destruction of cancer tissue. Our study aims at assess the safety&#xD;
      and effectiveness of such treatment in prostate cancer management&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oncological outcome-mpMRI prostate</measure>
    <time_frame>6 months</time_frame>
    <description>Oncological outcome after cryotherapy treatment, as defined by mpMRI prostate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oncological Outcomes after cryotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>Oncological outcome after cryotherapy treatment, as defined by mpMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome after cryotherapy</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Change in scores in EPIC-26 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication after study intervention</measure>
    <time_frame>30 days</time_frame>
    <description>Post treatment complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncological outcome-Biopsy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence of histologically proven prostate cancer recurrence on biopsy in suspicious cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen change</measure>
    <time_frame>3 months, 6 months, 9 months, 12 months</time_frame>
    <description>PSA change after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cryotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryotherapy achieves a temperature averaging -40Â°C. Through the transperineal insertion of treatment probes, it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryotherapy</intervention_name>
    <description>Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.</description>
    <arm_group_label>Cryotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged between 40 - 85 years&#xD;
&#xD;
          -  Visible index lesion(s) on MRI&#xD;
&#xD;
          -  Found to have localized prostate cancer after MRI-USG fusion targeted biopsy:&#xD;
&#xD;
               1. Clinical tumour stage &lt;= T2, or&#xD;
&#xD;
               2. Gleason score &lt;= 7, or&#xD;
&#xD;
               3. PSA &lt;= 20 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unfit for contrast MRI exam&#xD;
&#xD;
          -  Patients with active urinary tract infection&#xD;
&#xD;
          -  Patients with bladder pathology including bladder stone and bladder cancer&#xD;
&#xD;
          -  Patients with urethral stricture&#xD;
&#xD;
          -  Patients with neurogenic bladder and/or sphincter abnormalities&#xD;
&#xD;
          -  Patients who fail to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only man will develop prostate cancer</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chi Hang YEE, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chi Hang YEE, MBBS</last_name>
    <phone>+852 35052625</phone>
    <email>yeechihang@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <reference>
    <citation>Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004 Oct;172(4 Pt 1):1297-301.</citation>
    <PMID>15371827</PMID>
  </reference>
  <reference>
    <citation>Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015 Jan 20;33(3):272-7. doi: 10.1200/JCO.2014.55.1192. Epub 2014 Dec 15.</citation>
    <PMID>25512465</PMID>
  </reference>
  <reference>
    <citation>Kaye DR, Qi J, Morgan TM, Linsell S, Ginsburg KB, Lane BR, Montie JE, Cher ML, Miller DC; Michigan Urological Surgery Improvement Collaborative. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU Int. 2019 May;123(5):846-853. doi: 10.1111/bju.14554. Epub 2018 Oct 15.</citation>
    <PMID>30248225</PMID>
  </reference>
  <reference>
    <citation>Lindner U, Trachtenberg J, Lawrentschuk N. Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol. 2010 Oct;7(10):562-71. doi: 10.1038/nrurol.2010.142. Epub 2010 Sep 14. Review.</citation>
    <PMID>20842187</PMID>
  </reference>
  <reference>
    <citation>Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, van der Meulen J, Villers A, Willis S, Ahmed HU. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol. 2015 Apr;67(4):771-7. doi: 10.1016/j.eururo.2014.09.018. Epub 2014 Oct 1.</citation>
    <PMID>25281389</PMID>
  </reference>
  <reference>
    <citation>Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, Katz A, Pisters L, Rukstalis D, Shinohara K, Thrasher JB. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008 Nov;180(5):1993-2004. doi: 10.1016/j.juro.2008.07.108. Epub 2008 Sep 25. Review.</citation>
    <PMID>18817934</PMID>
  </reference>
  <reference>
    <citation>Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012 Jun;109(11):1648-54. doi: 10.1111/j.1464-410X.2011.10578.x. Epub 2011 Oct 28.</citation>
    <PMID>22035200</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Chi Hang Yee</investigator_full_name>
    <investigator_title>Honorary Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Focal therapy</keyword>
  <keyword>Cryotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

